Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Xiaflex collagenase clostridium histolyticum: Phase IIb data

December 21, 2009 8:00 AM UTC

Top-line data from a U.S. Phase IIb trial in 145 patients showed that Xiaflex significantly improved penile curvature from baseline to week 36 by 29.7% vs. 11% for placebo (p=0.001). Xiaflex also significantly improved the PRO Peyronie's disease bother domain from baseline to week 36 vs. placebo (p=0.046), but did not significantly improve mean scores in the PRO penile pain, intercourse discomfort or intercourse constraint domains vs. placebo. Additionally, 60.5% of patients treated with Xiaflex (n=109) achieved at least a 25% reduction in angle of curvature vs. 25% for placebo.

In a prospective subgroup of patients who received penile massaging of the collagen plaque on the shaft, which is intended to maximize the enzymatic effect of the compound, Xiaflex plus penile massaging significantly improved penile curvature by 32.4% vs. a 2.5% worsening for placebo plus penile massaging (p<0.001). Xiaflex without penile massaging did not significantly improve penile curvature vs. placebo (p=0.91). Xiaflex plus penile massaging also significantly improved the PRO Peyronie's disease bother domain vs. placebo plus penile massaging (p=0.004), whereas Xiaflex without penile massaging did not significantly improve any of the PRO domains vs. placebo. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article